MC-Rx

Powered by ProCare Rx

Current News: https://www.cdc.gov/coronavirus/2019-ncov/index.html

Volume 2020 #10

Prepared for 03/30/2020

Drug Information Updates

Eucrisa's Indication Extended **03/23/2020**

The FDA approved Eucrisa® (cisaborole) ointment, 2% for a pediatric indication in children as young as 3 months old. Eucrisa, applied lightly to affected areas twice a day, was approved in late 2016 to treat mild-to-moderate atopic dermatitis for patients age 2 years and older. Also known as eczema, atopic dermatitis includes a group of chronic skin diseases that involve inflammation and cause itchy, irritated bumps, crusts and scales on the skin. It usually begins in childhood, with approximately 45% of patients having their first outbreaks before the age of 6 months.

Formulary Status: Eucrisa is a tier 3 non-preferred brand drug on the National Formulary.

Gloperba Solution Launched **02/27/2020**

Gloperba® Oral Solution (colchicine), an FDA-approved oral liquid form of colchicine, was launched by Avion Pharmaceuticals in late February. Gloperba is to be taken twice every day in doses of 0.6mg (5mL) each to keep adults who have gout from experiencing attacks. Gloperba has not been studied for treating acute flares and it does not relieve pain associated with gout.

Formulary Status: Gloperba is a tier 3 non-preferred brand on the National Formulary.

Nexium Oral Solution Launched **03/23/2020**

Cipla has launched AB-rated generics for three strengths (10mg, 20mg, and 40mg) of AstraZeneca's Nexium® (esomeprazole magnesium) for oral suspension. Esomeprazole magnesium is approved to treat gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) conditions. It also is indicated to decrease the risk of both stomach ulcers from the use of non-steroidal anti-inflammatory drugs (NSAIDs) and the return of ulcers in the upper part of the small intestine. The generics are available in cartons of 30 individual-dose packets.

Zeposia Approved for Relapsing Forms of MS **03/25/2020**

Zeposia® (ozanimod) capsules, a sphingosine 1-phosphate (S1P) receptor modulator, was approved to treat adult patients with relapsing forms of multiple sclerosis (RMS), including relapsing-remitting multiple sclerosis (RRMS), clinically isolated syndrome (CIS), and active secondary progressive multiple sclerosis (SPMS). Before treatment begins, prescribers will need to do a baseline assessments for each patient, after which titration is required. Although approved, its launch is being delayed due to the COVID-19 pandemic. Zeposia will be dispensed through specialty pharmacies.

Formulary Status: Zeposia will be reviewed at the next P&T Committee meeting in June.

Epipen, Epipen Jr. & Authorized Generic Pen Warning **03/25/2020**

Mylan Pharmaceuticals is cautioning prescribers, pharmacies, patients, and caregivers of potential safety issues with EpiPen®, EpiPen Jr®, and their authorized generics (epinephrine auto-injectors) that some of the devices may have trigger issues. An EpiPen user should be sure that the safety release is tight, and then hold the auto-injector firmly in one hand with the orange end pointing down. Additionally, a small defect in the storage tubes in some devices may cause them to get stuck in the tubes, possibly resulting in additional time to pull out the auto-injector. Both issues could delay or prevent an injection. Patients or their caregivers should check each device they have to assure that it slides easily out of its tube and that the safety release is not sticking up from the top of the auto-injector. If either problem is found, the patient or caregiver should call Mylan at 800-796-9526 for directions on how to return the defective device for a free replacement.

IMPENDING FDA REVIEWS SCHEDULED FOR THE NEXT 2 WEEKS:

03/28 – Reblozyl® (luspatercept-aamt - Acceleron): New indication for activin receptor type IIB fusion protein to treat patients who have myelodysplastic syndrome (MDS)-associated anemia with ring sideroblasts; SC injection.

GENERAL INFORMATION:

For more information, please either visit FDA.gov or contact your account manager.